New Tumor Evaluation Modality To Measure Effectiveness Of Cancer Therapies

Background

Veristat was brought on to write a sponsor’s protocol for a novel treatment that injects engineered exosomes into solid tumors. The application of a set of nuanced response criteria required information collected from injected lesions and non-injected lesions to determine a tumor’s response to the treatment.

Study Demographics

• Indication: Advanced metastatic recurrent injectable solid tumors
• What Kind of Trial: Immunotherapy with intratumoral delivery
• Primary Services Provided:
  • Strategic consulting
  • Protocol development
  • Statistical analysis plan development
  • Project management

Download the available case study to learn more.